Filing Flows › Castle Biosciences (CSTL) › How it makes money
How Castle Biosciences (CSTL) makes money
Castle Biosciences (CSTL) made $103M of revenue in the third quarter 2026 (Q3 2026), +24% from a year earlier. Non-Dermatologic brought in $55.0M (53%); Dermatologic brought in $47.9M (47%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Non-Dermatologic | $55.0M | 53.5% | +0.3% | +59% |
| Dermatologic | $47.9M | 46.5% | -2% | -1% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $103M | 100.0% |
| Income tax | $298K | 0.3% |
| Operating cash flow | $19.7M | 19.2% |
| Free cash flow | $12.2M | 11.9% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $103M | +24% |
| Q2 2026 | $104M | +20% |
| Q1 2026 | $83.7M | -5% |
| Q4 2025 | $87.0M | +0.8% |
| Q3 2025 | $83.0M | -3% |
| Q2 2025 | $86.2M | -0.9% |
| Q1 2025 | $88.0M | +21% |
From Castle Biosciences' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Castle Biosciences make money?
Castle Biosciences (CSTL) made $103M of revenue in the third quarter 2026 (Q3 2026), +24% from a year earlier. Non-Dermatologic brought in $55.0M (53%); Dermatologic brought in $47.9M (47%).
What is Castle Biosciences' biggest business?
Non-Dermatologic: $55.0M in the third quarter 2026, 53% of revenue, +59% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.